Nephroblastoma overexpressed gene expression and its prognostic implications of clinical outcomes in renal cell carcinoma patients

Abstract

BACKGROUND:

The nephroblastoma overexpressed gene (NOV) expressions in tissues and organs has become abnormal during tumorigenesis and progression. This study intended to investigate the correlation between clinical outcomes and NOV expression in renal cell carcinoma (RCC) patients.

METHODS:

Fifty RCC patients who attended the hospital from January 2013 to January 2015 were enrolled in this study. NOV expression in cancerous tissues and adjacent non-tumor (ANT) renal tissues of RCC patients was detected by immunohistochemistry (IHC). According to the percentage of NOV-positive cells, cases were divided into NOV-positive and NOV-negative groups. The correlations between age, gender, disease course, tumor diameter, pathological grades (WHO/ISUP grading system) or tumor-node-metastasis (TNM) staging and NOV-positive rate were determined. Kaplan-Meier method was utilized for analyzing the 3- and 5-survial rates of RCC patients. The Cox proportional hazards regression model was used for the multivariate analysis.

RESULTS:

NOV-positive rate was uncorrelated with age, gender, disease course or TNM classification while was negatively correlated with pathological grades. NOV-positive rate in RCC tumor and ANT tissues was 58% and 100%, respectively. Five-year survival rate in NOV-positive group was significantly lower than that in NOV-negative group.

CONCLUSION:

Our data suggested that NOV down-regulation might be a biomarker for RCC but its positivity might be an indicator of poor prognosis.

Keywords

Nephroblastoma overexpressed gene renal clear cell carcinoma immunohistochemistry clinical outcome

1. Introduction

NOV (nephroblastoma overexpressed) also known as CCN3, belongs to a large family of CCN proteins, which are named after the first three members of the family being identified as cysteine-rich angiogenic inducer 61 (CYR61/CCN1), connective tissue growth factor (CTGF/CCN2) and NOV/CCN3 [1]. CCN proteins have regulatory roles in cell proliferation, differentiation, adhesion, migration and other processes. It is also involved in angiogenesis and fibrosis, which play important roles in tumor development [2, 3].

The expression of NOV has been shown in a variety of human tissues and organs including cartilage, brain, muscle, kidney, lungs, ovaries and etc. Interestingly, the NOV expressions in tissues and organs become abnormal during tumorigenesis and progression, suggesting NOV may play an important role in these processes [4, 5]. Changes of NOV expression level are different depending on the types of tumors. For example, in chondrosarcoma [6], osteosarcoma [7], chronic myeloid leukemia [8] and melanoma [9], overexpression of NOV inhibits the proliferation and progression of tumors. In contrast, NOV overexpression promotes the proliferation of 3T3 fibroblasts [10] and the metastasis of prostate tumors [11].

During the development of human kidney, NOV is involved in regulating glomerular podocyte differentiation [12]. Chevalier et al. found that the NOV expression in human nephroblastoma was positively correlated with the degree of tumor differentiation, suggesting NOV overexpression inhibited the initiation and development of nephroblastoma [12]. However, whether the NOV expression is correlated with clinical outcomes in renal clear cell carcinoma (RCC) patients is unknown and there is no biomarker for prognostication in RCC yet. Thus, the understanding of the clinicopathological value of NOV expression could be beneficial for RCC patients.

In this study, we investigated the correlation between clinical outcomes and NOV overexpression in RCC patients. We observed that the NOV was 100% positive in RCC tumors and 58% in adjacent non-tumor (ANT) tissues though the expression levels of NOV was significantly lower in RCC tumors. The five-year survival rate was higher in NOV positive group, and percentage of RCC in G grade was negatively correlated with percentage of NOV overexpression in RCC patients.

Table 1
Comparison of general characteristics between nephroblastoma overexpressed (NOV) positive and NOV negative groups in renal cell carcinoma patients

	NOV positive	NOV negative	$p$ value
	( $n=$ 29)	( $n=$ 21)
Gender (male/female)	15/14	11/10	0.96
Age (year)	45.4 $\pm$ 8.5	44.1 $\pm$ 6.7	0.54
Course of disease (year)	1.8 $\pm$ 0.4	1.9 $\pm$ 0.5	0.44

Table 2

Comparison of nephroblastoma overexpressed (NOV)-positive rates (NOV-PR) between NOV positive and NOV negative groups in renal cell carcinoma tumor tissues and adjacent non-tumor (ANT) tissues

N (NOV-PR)	NOV ( $+$ $+$ $+$ )	NOV ( $+$ $+$ )	NOV ( $+$ )	NOV ( $-$ )	NOV positive
ANT tissues	50 (100%)	0 (0%)	0 (0%)	0 (0%)	50 (100%)
RCC tumor tissues	1 (2%)	24 (48%)	4 (8%)	21 (42%)	29 (58%)

Table 3

Correlation between tumor diameter and expression of nephroblastoma overexpressed (NOV)-positive rate (NOV-PR) in renal cell carcinoma

Tumor	$N$	NOV		$\chi^{2}$	$P$ value
diameter		Positive	Negative
$<$ 4 cm	15	10 (66.67%)	5 (33.33%)	0.66	0.42
$\geqslant$ 4 cm	35	19 (54.29%)	16 (45.71%)	0.66	0.42

2. Methods

2.1 Patient characteristics

A total of 50 cases of patients with RCC, who were admitted to General Hospital of Ningxia Medical University and Xi’an Central Hospital from January 2013 to January 2015, were enrolled in this study. The study was carried out with informed consents from patients and approved by the Ethics Committee of our hospital.

The inclusion criteria were: 1) patients with RCC confirmed with biopsy by pathologist; 2) patients without severe damage in heart, liver, kidney and other vital organs; disorder of consciousness; malignant disease; or bleeding disorders.

The exclusion criteria were: 1) patients with diseases associated with heart, kidney, liver, brain and other major organs or disorder of consciousness; 2) patients who were pregnant or lactating. Patients’ age ranged from 31 to 65 years. The data of basic clinical characteristics were summarized in Table 1.

2.2 Immunohistochemistry (IHC) and scoring for NOV expression

After dissection, all tumor samples were fixed in 10% formalin at room temperature overnight, followed by dehydrating in a gradient ethanol series, clearing with xylene, and embedding in paraffin blocks. IHC was used to detect the NOV expression in tumor and ANT tissues in patients with RCC. Briefly, each patient tissue samples were continuously sectioned in paraffin with a thickness of 4 $\mu$ m. Xylene was used for dewaxing and gradient ethanol was used for hydration. After antigen retrieval in citrate solution by microwave for 10 min, the slices were incubated with primary rabbit polyclonal CCN3 antibody (1:250, Abcam, Cambridge, UK) at 4 ${}^{\circ}$ C overnight, followed by incubation with the secondary antibody of HRP-conjugated goat anti-rabbit IgG (1:1000, Abcam) at 37 ${}^{\circ}$ C for 1 h. Immunoactivity was detected by staining with 3, 3 ${}^{\prime}$ -diaminobenzidine (DAB) and then the slices were counter-stained with Hematoxylin-Eosin.

The IHC staining was evaluated by two independent assessors with pathological training following assessor-blind protocol. The immunoreactive score (IRS), which was calculated as staining intensity (SI) $\times$ percentage of positive cells (PP), was utilized to evaluate NOV expression [13]. SI was determined as 0, negative; 1, weak; 2, moderate; and 3, strong. PP was defined as 0, negative; 1, less than 5% positive cells; 2, 5%–25% positive cells; 3, 26%–50% positive cells; and 4, more than 50% positive cells.

2.3 Clinical indexes

General information and survival rate of NOV positive patients and NOV negative patients were compared. Correlation between NOV expression and RCC tumor size, stage and grade were analyzed. The pathological classification was performed according to the World Health Organization (WHO)/International Society of Urologic Pathologists (ISUP) grading system [14] and tumor-node-metastasis (TNM) staging was performed according to the International Union against Cancer in 2002, version 6 of TNM stage [15]. The criteria of NOV positive staining was brown staining in the cytoplasm and cell membrane. According to the PP, there were four levels: NOV negative ( $-$ ): total number of positive cells was $<$ 5%; NOV weak positive ( $+$ ): total number of positive cells ranged from 5% to 25%; NOV moderate positive ( $+$ $+$ ): the total number of positive cells ranged from 26% to 50%; NOV strong positive ( $+$ $+$ $+$ ): total number of positive cells was $>$ 50% [5].

2.4 Statistical analysis

Univariate survival analyses were performed using the Kaplan-Meier method. The Cox proportional hazards regression model was used for the multivariate analysis. Chi-square was performed to compare categorical variables between groups using SPSS software (version 15.0; SPSS, Inc., Chicago, IL, USA). The difference was considered statistically significant when $P<$ 0.05.

3. Results

3.1 Clinical characteristics of patients

A total of 29 patients, including 15 males and 14 females with an average age of 45.4, were enrolled in the NOV positive group. There were 11 males and 10 females in the NOV negative group with an average age at 44.1. The average disease course was 1.8-year and 1.9-year in NOV positive and NOV negative groups, respectively. The differences of these characteristics between the two groups were non-significant ( $P>$ 0.05; Table 1).

Figure 1.

Immunohistochemistry analysis of nephroblastoma overexpressed (NOV) expression in adjacent non-tumor (ANT) kidney tissue (A) and tumor tissues (B) of renal cell carcinoma. (A: 200X; B: 400X).

Figure 2.

Kaplan-Meier survival curves of patients with positive or negative nephroblastoma overexpressed (NOV) expressions (A: 3-year survival; B: 5-year survival).

3.2 NOV expression in both RCC tumors and ANT kidney tissues

By IHC, the NOV-positive staining was mainly observed in the cytoplasmic membrane and the IHC staining of ANT and RCC tissues were shown in Fig. 1. In total 50 patients, all ANT tissues but 29 cases of RCC tissues were found to be positive NOV expression (Table 2). The overall NOV-positive rate in ANT kidney tissues was 100% while in RCC tumor tissues was 58%. However, the staining score for NOV in RCC tissues was significantly higher than that in ANT renal tissues (2.26 $\pm$ 0.3 vs. 0.33 $\pm$ 0.12 score units, $P<$ 0.0001).

3.3 Correlation between NOV expression and tumor diameter or patient survival rate

There were 15 cases with tumor diameter less than 4 cm and 35 cases with tumor diameter larger than or equal to 4 cm. There were more cases with NOV-positivity than that in NOV negative group no matter what the tumor diameter was, but statistical analysis showed that tumor diameter was not significantly correlated with NOV positive rate in RCC patients ( $\chi^{2}=$ 0.66, $P=$ 0.42; Table 3). Furthermore, we also investigated the correlation between NOV expression and 3-year or 5-year survival rates in RCC patients. Our data suggested that 3-year survival rate in NOV positive group was lower than that in the NOV protein negative group (76.19% vs. 89.65%), along with non-significant difference. Analogically, the 5-year survival rate of patients with NOV positivity was markedly lower than NOV negativity (42.85% vs. 75.86%, $\chi^{2}=$ 5.63, $P=$ 0.0176; Fig. 2).

3.4 Correlation between NOV expression and pathological classification (grades), TNM stages or clinical outcomes in RCC

To further explore the correlation between RCC and NOV expression, we investigated the NOV-positive rate in different grades and TNM stages. There were 13, 24 and 13 cases, showing NOV positivity, in G1, G2 and G3 stages, respectively (Table 4). Meantime, the numbers of cases with NOV negativity in G1, G2 and G3 stages were 3, 11 and 6, respectively. Statistical analysis showed that the positive rate of NOV in each grade was decreased along with the increase of grades ( $P<$ 0.05). There were 18, 15, 10 and 7 cases in T1 to T4 stages and 34, 11 and 5 cases in NM stages, presenting NOV positivity. The numbers of cases with NOV negativity in T1 to T4 stages were 7, 6, 4 and 4, and in NM stages were 10, 7 and 4, respectively. We didn’t observe any significant correlation between NOV positive rate and TNM stages in RCC patients. Further multivariate analysis of clinical parameters for predicting prognosis using Cox proportional hazards regression model also confirmed that NOV positivity was the single factor that significantly correlated with clinical outcomes ( $P=$ 0.003, Table 5).

Table 4
Expression of nephroblastoma overexpressed (NOV) in renal cell carcinoma with different grades and tumor-node-metastasis (TNM) stages

	$N$	NOV		$P$ value
		Positive	Negative
Grade				$<$ 0.05
G1	13	11 (78.58%)	3 (21.42%)
G2	24	13 (54.17%)	11 (45.83%)
G3	13	5 (45.45%)	6 (54.55%)
T stage				0.57
T1	18	11 (61.11%)	7 (38.89%)
T2	15	9 (60.00%)	6 (40.00%)
T3	10	6 (60.00%)	4 (40.00%)
T4	7	3 (42.86%)	4 (57.14%)
NM stage				0.47
N ${}_{0}$ M ${}_{0}$	34	24 (70.59%)	10 (29.41%)
N ${}_{1\sim 3}$ M ${}_{0}$	11	4 (36.36%)	7 (63.64%)
N ${}_{1\sim 3}$ M ${}_{1}$	5	1 (20.00%)	4 (80.00%)

Grades were classified according to the World Health Organization (WHO)/International Society of Urologic Pathologists (ISUP) grading system; T staging was classified according to the TNM system.

Table 5

Multivariate analysis of clinical parameters for predicting prognosis using Cox proportional hazards regression model

Category	B	SE	95.0% CI	$P$ value
NOV expression	$-$ 1.644	0.556	0.065–0.575	0.003
Gender	$-$ 1.105	0.574	0.108–1.020	0.054
Age	$-$ 0.015	0.031	0.926–1.047	0.620
Course of disease	$-$ 0.499	0.502	0.227–1.623	0.320
Grade	$-$ 0.304	0.426	0.320–1.701	0.476
T staging	$-$ 0.239	0.232	0.500–1.241	0.303
Tumor diameter	0.245	0.587	0.404–4.041	0.677
TNM staging	$-$ 0.463	0.373	0.303–1.307	0.215

NOV, nephroblastoma overexpressed; TNM, tumor-node-metastasis (TNM). Grades were classified according to the World Health Organization (WHO)/International Society of Urologic Pathologists (ISUP) grading system; T staging was classified according to the TNM system.

4. Discussion

In this study, expression of NOV in RCC tumor and ANT tissues as well as the relationship between NOV expression and clinical characteristics were evaluated. Statistical results showed there was no link between NOV-positive rat and gender, age, disease course or tumor diameter. The NOV-positive rates in RCC tumor and ANT kidney tissues were 58% and 100%, respectively. However, the NOV staining scores in RCC tumor was significantly higher than that in ANT tissue. Kaplan-Meier analysis suggested that NOV-positive may be an indicator of poor prognosis in RCC and multivariate analysis of clinical parameters also proved the suggestion.

NOV, initially discovered in nephroblastoma, is implicated in multiple cancers, such as leukemia, breast cancer and melanoma [16]. NOV is locus on chromosome 8q24 and is supposed to be implicated in RCC, since mutation in chromosome 8q is common chromosomal abnormalities kidney cancer in particular RCC [17, 18]. Studies have shown that NOV mRNA expression levels were significantly lower in RCC tumor than that in the normal kidney tissue [19]. Accumulating evidence illustrates that NOV exhibits tumor-suppressive roles. In myoblasts, NOV binds to the epidermal growth domain of Notch1 and activates the Notch signaling pathway to play a role in the inhibition of cell proliferation [20]. In C6-glioma cell line, NOV mainly interacts with the cell gap protein Connexin43 to inhibit cell proliferation [21]. However, the literatures focused on the association between NOV and RCC are limited. In our study, the NOV-positive rate of RCC tumor tissues was lower than that of ANT tissues, and was negatively correlated with tumor grades. The age, gender, disease course, tumor diameter and T/N/M classification could not affect NOV-positive rate significantly. Results suggested a possible predictive role of NOV-positive rate in RCC.

Meanwhile, a previous study showed NOV could promote breast cancer metastasis to bone through stimulation of osteoclast differentiation [22]. Additionally, NOV increases cell motility in various cancer types, including prostate cancer [23], chondrosarcoma [24] and RCC [25]. These observations suggested an oncogenic role of NOV. In our study, IHC scores showed significant increase in RCC tumor tissues compared with ANT tissues. The following Kaplan-Meier analysis showed the 5-year survival rate of NOV-positivity was lower than NOV-negativity (IHC scores). Multivariate analysis presented NOV was a significant predictor for prognosis. These results stated that NOV might be an indicator of poor prognosis for RCC, which was coincidence with the reporter of Ueda and colleagues [26].

The mechanism of NOV in tumor initiation has not been fully investigated. NOV interacts with the extracellular matrix and cell surface molecules that regulate a variety of cellular expression and activity status, and participates in a variety of signal transduction pathways [20]. NOV is associated with progression of RCC [27]. Though this pilot study is limited due to its relatively small sample size, the potential of NOV as a clinical marker for evaluating the progression of RCC could be beneficial for patients. However, further studies with larger sample size are warranted in the near future. Moreover, more details on the functional role of NOV in RCC cells should be fully investigated using molecular methods.

5. Conclusions

In conclusion, our results showed NOV-positive rate was lower in RCC tumor tissues and was negatively correlated with grades. NOV-positive rate was uncorrelated with age, gender, disease course or TNM classification. In addition, 5-year survival of NOV-positive group was lower than the NOV-negative group, indicating higher NOV was correlated with poor prognosis. Our study implied NOV down-regulation was a biomarker of RCC but its up-regulation was an indicator of poor prognosis in RCC.

References

Perbal

, The CCN family of genes: A brief history, Mol Pathol 54 (2001), 103–104.

Inoki

Shiomi

Hashimoto

Enomoto

Nakamura

Makino

Ikeda

Takata

Kobayashi

and Okada

, Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis, Faseb J 16 (2002), 219–221.

Leask

, Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma, Cell Signal 20 (2008), 1409–1414.

Martinerie

Huff

Joubert

Badzioch

Saunders

Strong

and Perbal

, Structural analysis of the human nov proto-oncogene and expression in Wilms tumor, Oncogene 9 (1994), 2729–2732.

Martinerie

Chevalier

Rauscher

F.J.

and Perbal

, Regulation of nov by WT1: A potential role for nov in nephrogenesis, Oncogene 12 (1996), 1479–1492.

Tzeng

H.E.

Chen

J.C.

Tsai

C.H.

Kuo

C.C.

Hsu

H.C.

Hwang

W.L.

Fong

Y.C.

and Tang

C.H.

, CCN3 increases cell motility and MMP-13 expression in human chondrosarcoma through integrin-dependent pathway, J Cell Physiol 226 (2011), 3181–3189.

Yao

Weng

Yan

Hou

Wang

Shi

and Zuo

, NOV inhibits proliferation while promoting apoptosis and migration in osteosarcoma cell lines through p38/MAPK and JNK/MAPK pathways, Oncol Rep 34 (2015), 2011–2021.

McCallum

Price

Lazar

Perbal

and Irvine

A.E.

, CCN3 suppresses mitogenic signalling and reinstates growth control mechanisms in Chronic Myeloid Leukaemia, J Cell Commun Signal 6 (2012), 27–35.

Vallacchi

Daniotti

Ratti

Di Stasi

Deho

De Filippo

Tragni

Balsari

Carbone

Rivoltini

Parmiani

Lazar

Perbal

and Rodolfo

, CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma, Cancer Res 68 (2008), 715–723.

10.

Liu

X.J.

Crowe

P.D.

Kelner

G.S.

Fan

Barry

Manu

Ling

De Souza

E.B.

and Maki

R.A.

, Nephroblastoma overexpressed gene (NOV) codes for a growth factor that induces protein tyrosine phosphorylation, Gene 238 (1999), 471–478.

11.

Chen

P.C.

Cheng

H.C.

and Tang

C.H.

, CCN3 promotes prostate cancer bone metastasis by modulating the tumor-bone microenvironment through RANKL-dependent pathway, Carcinogenesis 34 (2013), 1669–1679.

12.

Chevalier

Yeger

Martinerie

Laurent

Alami

Schofield

P.N.

and Perbal

, novH: Differential expression in developing kidney and Wilm’s tumors, Am J Pathol 152 (1998), 1563–1575.

13.

Luo

F.Y.

Liu

Z.H.

Q.H.

Lin

G.Q.

Tang

C.E.

Zhang

W.X.

and Zhuang

, Association of BTBD7 with metastasis and poor prognosis in non-small-cell lung cancer patients, Journal of Cancer 6 (2015), 477–481.

14.

Mostofi

F.K.

Davis

C.J.

and Sesterhenn

I.A.

, WHO histological typing of urinary bladder tumors, 1973.

15.

Sobin

L.H.

and Wittekind

C.H.

, International union against cancer (UICC), 2002.

16.

Runkle

Jin

H.J.

Yang

Kuzel

Lee

and Yu

, CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor, Oncogene 33 (2014), 504.

17.

Grisanzio

Seeley

Chang

Collins

Napoli

A.D.

Cheng

S.C.

Percy

Beroukhim

and Signoretti

, Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients, Journal of Pathology 225 (2011), 212–221.

18.

Brisbin

A.G.

Asmann

Y.W.

Song

Ya-Yu

Aakre

J.A.

Yang

Jenkins

R.B.

Paul

Fredrick

and Conti

D.V.

, Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development, BMC Medical Genetics 12 (2011), 156.

19.

Liu

Yuan

Liu

Ding

and Niu

, CCN3 (NOV) regulates proliferation, adhesion, migration and invasion in clear cell renal cell carcinoma, Oncol Lett 3 (2012), 1099–1104.

20.

Sakamoto

Yamaguchi

Ando

Miyawaki

Kabasawa

Takagi

C.L.

Perbal

and Katsube

, The nephroblastoma overexpressed gene (NOV/ccn3) protein associates with Notch1 extracellular domain and inhibits myoblast differentiation via Notch signaling pathway, J Biol Chem 277 (2002), 29399–29405.

21.

Sin

W.C.

Bechberger

J.F.

Rushlow

W.J.

and Naus

C.C.

, Dose-dependent differential upregulation of CCN1/Cyr61 and CCN3/NOV by the gap junction protein Connexin43 in glioma cells, J Cell Biochem 103 (2008), 1772–1782.

22.

Ouellet

Tiedemann

Mourskaia

Fong

J.E.

Tranthanh

Amir

Clemons

Perbal

Komarova

S.V.

and Siegel

P.M.

, CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone, American Journal of Pathology 178 (2011), 2377–2388.

23.

Chen

P.C.

Lin

T.H.

Cheng

H.C.

and Tang

C.H.

, CCN3 increases cell motility and ICAM-1 expression in prostate cancer cells, Carcinogenesis 33 (2012), 937–945.

24.

Tzeng

H.E.

Chen

J.C.

Tsai

C.H.

Kuo

C.C.

Hsu

H.C.

Hwang

W.L.

Fong

Y.C.

and Tang

C.H.

, CCN3 increases cell motility and MMP-13 expression in human chondrosarcoma through integrin-dependent pathway, Journal of Cellular Physiology 226 (2011), 3181.

25.

Liu

Yuan

Liu

Ding

and Niu

, CCN3 (NOV) regulates proliferation, adhesion, migration and invasion in clear cell renal cell carcinoma, Oncology Letters 3 (2012), 1099.

26.

Ueda

Iguchi

Komatsu

Kidogami

Sato

Ogawa

Nambara

Saito

and Sakimura

, Clinical significance of expression of nephroblastoma overexpressed (NOV) in patients with colorectal cancer, Anticancer Research 35 (2015), 6591–6597.

27.

Glukhova

Angevin

Lavialle

Cadot

Terrier-Lacombe

M.J.

Perbal

Bernheim

and Goguel

A.F.

, Patterns of specific genomic alterations associated with poor prognosis in high-grade renal cell carcinomas, Cancer Genet Cytogenet 130 (2001), 105–110.

Nephroblastoma overexpressed gene expression and its prognostic implications of clinical outcomes in renal cell carcinoma patients

Abstract

BACKGROUND:

METHODS:

RESULTS:

CONCLUSION:

Keywords

1. Introduction

Table 1 Comparison of general characteristics between nephroblastoma overexpressed (NOV) positive and NOV negative groups in renal cell carcinoma patients

2.1 Patient characteristics

2.2 Immunohistochemistry (IHC) and scoring for NOV expression

2.3 Clinical indexes

2.4 Statistical analysis

3. Results

3.1 Clinical characteristics of patients

3.3 Correlation between NOV expression and tumor diameter or patient survival rate

3.4 Correlation between NOV expression and pathological classification (grades), TNM stages or clinical outcomes in RCC

Table 4 Expression of nephroblastoma overexpressed (NOV) in renal cell carcinoma with different grades and tumor-node-metastasis (TNM) stages

5. Conclusions

References

Table 1
Comparison of general characteristics between nephroblastoma overexpressed (NOV) positive and NOV negative groups in renal cell carcinoma patients

Table 4
Expression of nephroblastoma overexpressed (NOV) in renal cell carcinoma with different grades and tumor-node-metastasis (TNM) stages